VivoSeq
Other

Decreased Liver Function

3

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Decreased liver function is an early-stage landscape with 3 programs across 3 companies. The most active players are Bayer, Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Salix. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

ApprovedS

Salix

1 program

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

BAY3427080

Bayer

Phase 2
No programs
Phase 3
No programs
Approved2

Deucravacitinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Methylnaltrexone

Salix

Analysis

Trial Status

1

clinical trials

Completed1 · 100%

Clinical Trials

Trial Activity

A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants
Completed·Bayer logoBayer·Phase 1·NCT04903821·33 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)